Caron Jacobson, MD, MMSc, is an associate professor of medicine at Harvard Medical School and the medical director of the Immune Effector Cell Therapy Program at the Dana-Farber Cancer Institute, which oversees the commercial and research programs of engineered cellular therapies across hematologic malignancies and solid tumors. She is also a lymphoma clinical investigator, and her research interests involve the clinical and translational study of chimeric antigen receptor (CAR) T-cells and other cellular therapies for the treatment of B-cell non-Hodgkin lymphoma.
Dr. Jacobson is the principal investigator for several CAR T-cell studies at Dana-Farer, which incorporates immune profiling by CyTOF as well as multi-plex immunohistochemistry, and genomic and transcriptional sequencing on patient samples. She was awarded the NCI Cancer Clinical Investigator Team Leadership Award to develop and grow a clinical and research enterprise in immune effector cell therapies for the treatment of cancer at Dana-Farber.
Dr. Jacobson is board certified in hematology, internal medicine, and medical oncology. She earned an MMSc from Harvard Medical School and completed her fellowship in hematology/oncology at Dana-Farber Cancer Institute. She completed her residency in internal medicine at Columbia University and New York-Presbyterian Hospital, where she also attended medical school.